帕利哌酮緩釋片對精神分裂癥的療效及安全性分析

程亞玲　韓海斌

【摘 要】目的：探討帕利哌酮緩釋片對精神分裂癥的療效及安全性分析。方法：選擇從2016年1月至2018年12月收治的100例精神分裂癥患者為對象，采用隨機數(shù)字表法分為2組，命名為對照組（50例）與研究組（50例）。對照組給予阿立哌唑口腔崩解片治療，研究組給予帕利哌酮緩釋片治療，兩組均持續(xù)治療1個月。結(jié)果：研究組患者的臨床治療總有效率為92.00%，明顯高于對照組的70.00%，差異有統(tǒng)計學意義（=7.8622，P<0.05）;研究組患者治療前的PANSS評分與對照組比較，差異無統(tǒng)計學意義（t=0.0130，P>0.05）;研究組患者治療后7dPANSS評分為（60.90±12.25）分，治療后14dPANSS評分為（52.55±15.55）分，治療后28dPANSS評分為（40.10±15.75）分，明顯低于對照組的（69.85±12.10）分，（60.60±15.70）分，（49.60±13.70）分，差異有統(tǒng)計學意義（t=2.9560，2.0927，2.6143，P<0.05）;研究組患者的不良反應(yīng)發(fā)生率為4.00%，明顯低于對照組的20.00%，差異有統(tǒng)計學意義（=6.0606，P<0.05）。結(jié)論：對精神分裂癥實施帕利哌酮緩釋片治療的療效確切，且安全性高，值得推廣應(yīng)用。

【關(guān)鍵詞】帕利哌酮緩釋片;精神分裂癥;療效;安全性

Abstract：Objective investigate the efficacy and safety of paliperidone sustained-release tablets in schizophrenia.Methods One hundred patients with schizophrenia who were admitted from January 2016 to December 2018 were enrolled in the study.They were randomly divided into two groups and named as control group （50 cases） and study group （50 cases）.The control group was treated with aripiprazole orally disintegrating tablets， and the study group was given paliperidone sustained-release tablets.Both groups were treated for 1 month.Results The total effective rate of clinical treatment in the study group was 92.00%， which was significantly higher than that in the control group （70.00%）.The difference was statistically significant （2=7.8622， P<0.05）.The PANSS score of the study group before treatment was compared with the control group.The difference was not statistically significant （t=0.0130， P>0.05）.The PANSS score was （60.90±12.25） on the 7th day after treatment， and the PANSS score was （52.55±15.55） on the 14th day after treatment.The PANSS score was （40.10） on the 28th day after treatment.±15.75）， significantly lower than the control group （69.85±12.10）， （60.60±15.70）， （49.60±13.70）， the difference was statistically significant （t=2.9560， 2.0927， 2.6143， P<0.05） The incidence of adverse reactions in the study group was 4.00%， which was significantly lower than that in the control group （20.00%）， and the difference was statistically significant （2=6.0606， P<0.05）.Conclusion The efficacy of paliperidone sustained-release tablets in the treatment of schizophrenia is accurate and safe， and it is worthy of popularization and application.

【中圖分類號】R971.4【文獻標識碼】A【文章編號】1005-0019（2019）22-0-01

精神分裂癥為臨床常見的精神類疾病，該疾病具有慢性遷延、反復(fù)發(fā)作特點。目前臨床治療精神分裂癥的基本原則為積極控制癥狀表現(xiàn)，以及積極控制陽性體征，從而降低病情復(fù)發(fā)率，以提高患者的社會功能，提高患者的生活質(zhì)量。但是，由于精神分裂癥患者的治療依從性較差，而且中斷藥物治療容易導致病情復(fù)發(fā)。因此，臨床需加強重視[1-2]。本次研究工作旨在探討帕利哌酮緩釋片對精神分裂癥的療效及安全性分析。現(xiàn)報道如下。